Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 419-423

  Borand, Laurence ^a   Laureillard, Didier ^b   Madec, Yoann ^c   Chou, Monidarin ^d   Pheng, Phearavin ^a   Marcy, Olivier ^a   Sok, Thim ^e   Goldfeld, Anne E ^e,f   Taburet, Anne Marie ^g   Blanc, François Xavier ^g  

^a INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^b ANRS   (Viet Nam)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF HEALTH SCIENCES   (Cambodia)

^e Cambodian Health Committee   (Cambodia)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; BODY WEIGHT; COINFECTION; HIV INFECTIONS; HUMANS; TUBERCULOSIS; VIRAL LOAD;

EID: 84878102923     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2483     Document Type: Article

References (20)

1. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012; 68:689-695.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. (Accessed 15 August 2012.) Available from http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf
3. US Food and Drug Administration. Sustiva labeling update/dosing adjustment with rifampin. (Updated 3 February 2012. Accessed 15 August 2012.) Available from http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm294476.htm
4. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
5. British HIV Association. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. (Updated 30 April 2012. Accessed 15 August 2012.) Available from http://www.bhiva.org/documents/ Guidelines/Treatment/2012/120430TreatmentGuidelines.pdf
6. Yeni P. Management of people living with HIV/AIDS: recommendations from the French expert panel. French. (Updated 19 July 2010. Accessed 15 August 2012.) Available from http://www.sante.gouv.fr/IMG/pdf/Rapport-2010-sur-la- prise-en-charge-medicale-des-personnes-infectees-par-le-VIH-sous-la-direction- du-Pr--Patrick-Yeni.pdf
7. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-1481.
8. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
9. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19:1481-1486. (Pubitemid 41400693)
10. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-695.
11. Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011; 16:527-534.
12. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-1302. (Pubitemid 44884158)
13. Rekić D, Röshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 2011; 71:536-543.
14. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-690.
15. López-Cortés LF, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 2006; 58:1017-1023.
16. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-132. (Pubitemid 41818129)
17. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19:1541-1543. (Pubitemid 41400701)
18. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400. (Pubitemid 40065906)
19. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic- pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54:4432-4439.
20. Trancart S, Charreau I, Marchou B, et al. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. Antimicrob Agents Chemother 2012; 56:1655-1657.